ABSTRACT BACKGROUND Aging populations show higher incidences of myocardial infarction (MI) and heart failure (HF). Cardiac
N oncommunicable diseases, notably cancer, diabetes, cardiovascular and neurological disorders, account for 65.5% of deaths (approximately 34.5 million) worldwide (1) . Nearly 45% of these deaths are due to cardiovascular disease (CVD), which remains the leading cause of mortality worldwide (1) . Myocardial infarction (MI) leading to chronic heart failure (HF)
is the most common form of CVD that is prevalent in our society, and its incidence increases dramatically with age. The loss of cardiac tissue and ensuing impaired contractile function due to MI results in cardiac remodeling and cardiac hypertrophy, fibrosis, and altered autophagic activity. In older patients, all these processes are more pronounced (2) , although the molecular rationale remains unclear.
Autophagy, a process that recycles cellular components to maintain cellular homeostasis, is deregulated in age-related disease, like HF (3). Indeed, cardiacspecific deletion of the autophagy gene Atg5 in mice leads to a progressive decline in function with age, together with early appearance of other cardiac aging hallmarks (cardiac hypertrophy and fibrosis) eventually leading to premature death (4) . Temporally controlled deletion of Atg5 in adult mice also results in cardiac dysfunction, hypertrophy, disorganized sarcomere, mitochondria aggregation, and accumulation of ubiquitinated proteins (5) . Importantly, in the case of MI, accumulation of p62 colocalized aggresomes has been observed in the infarct border zone and in remote areas (6) This phenotype is lost when Mst1 À/À are crossed with Beclin þ/À mice, which show lower autophagic activity (6) . Therefore, the identification of therapeutic targets that modulate autophagy holds great promise as a new treatment approach to cardiac remodeling and HF, especially in older age.
Microribonucleic acids (miRNAs) are a class of noncoding regulatory ribonucleic acid (RNA) molecules of around 22 nucleotides in length; they exert their function by complementary binding via their seed sequence. In the past decade, miRNAs have been identified as critical regulators of cardiac pathophysiology (7) (8) (9) , but only a few miRNAs regulating cardiac autophagy have been studied in detail (10) . miRNA-212/132 was demonstrated to have prohypertrophic and antiautophagic effects in cardiomyocytes via regulation of FoxO3a (8) . Additionally, the miRNAs miR-199a and -221 have been reported to be antiautophagic, thus promoting cardiac hypertrophy (11, 12) .
We conducted a detailed functional study of 380 miRNAs to gain further insight into miRNA-dependent regulation of cardiac autophagy. We identified miR-22
as a strong inhibitor of cardiac autophagy using in vitro and preclinical in vivo models of MI in young and older mice. Likewise, the prognostic importance of circulating miR-22 was tested in a clinical cohort of 198 patients with systolic heart failure. MiR-22 Inhibits Cardiac Autophagy Figure 1E) . Certain miRNA hits were individually validated ( Figure 1D ).
Next, we compared the identified autophagic miRNA regulators with the cardiac miRNA expression profile and identified miR-22 to be highly abundant and have a strong autophagy inhibitory function ( Figure 1E ). miR-22 has been reported as a pro-hypertrophic miRNA (14, 16, 17) . Its inhibition abolished cardiac hypertrophy, whereas its overexpression resulted in massive hypertrophy (14, 16) . Previously, our group reported miR-22 to be induced during aging in murine hearts (18) . Cardiac miR-22 expression levels were confirmed in mice of different ages, from 4 days to 1.7
years. We found a 3-fold up-regulation at 3 months of age compared with younger control subjects followed by a further gradual increase with age ( Figure 3A) . MiR-22 Inhibits Cardiac Autophagy Global longitudinal strain ( Figure 5G ) and global Our studies of intracellular miR-22 levels in vitro and in vivo prompted us to also assess levels of circulating miR-22 in patients with systolic HF from ischemic and nonischemic origin. Indeed, the existence of other abbreviations as in Figures 1 and 3 . Table 2 ). The patients who died during the 3-year follow-up had significantly higher New York Heart Association functional class, brain natriuretic protein, and creatinine levels, and lower peak VO 2 .
The mean normalized delta cycle threshold (dCt) value for miR-22 was À4.11 AE 0.91 (range: À6.57
to À1.94). There was no association between age and and found miR-22 to be highly expressed in muscle tissue followed by aorta, lung, and liver ( Figure 7C) .
Thus, the source of higher circulating miR-22 likely is the heart together with other organs, such as the liver.
DISCUSSION
We demonstrated that miR-22 is a key regulator of cardiac autophagy and shows therapeutic potential as a novel target to treat post-infarct remodeling, especially in older mice. Balanced autophagic activity is necessary for the healthy functioning of the heart.
Autophagy is reported to be regulated by several Atg genes, whereas only some miRNAs are known to control myocardial autophagy (10) . We performed a large functional screening approach for miRNAs to (J) Cardiac cross-sectional measurements with wheat germ agglutinin staining showing increased area in infarcted hearts compared with sham; this was also reflected in (K) the frequency distribution of area measurements and (L) stained segments. n ¼ 5 to 6 sham; n ¼ 11 to 12 LNA-scramble; and n ¼ 11 LNA-anti-miR-22. Scale bar ¼ MiR-22 Inhibits Cardiac Autophagy
